童乐口服液对哮喘大鼠的干预研究
|
摘要
目的探讨童乐口服液对哮喘大鼠的干预作用及机制。方法通过卵蛋白激发诱导建立大鼠哮喘模型,以孟鲁司特钠为阳性对照,用不同剂量的童乐口服液进行干预,用化学发光法检测血清中免疫球蛋白E(Ig E)和白介素(IL-4、IL-10)。结果经童乐口服液灌胃给药后,哮喘大鼠免疫球蛋白E和白细胞介素(IL-4、IL-10)与模型组有显著差异(P<0.05),与正常对照组无显著差异(P>0.05)。结论童乐口服液可显著性降低哮喘大鼠的免疫球蛋白E和白细胞介素4水平,升高白细胞介素10的水平,抗炎机理可能与抑制Th2类细胞因子的活性有关。
Objective To investigate the intervention effect and mechanism of Tongle Oral Liquid on asthmatic rats.Methods The rat model of asthma was induced by ovalbumin.The immunoglobulin Ig E and interleukin( IL-4,IL-10) in serum were detected by chemiluminescence methods. The asthmatic rats were treated with different doses of Tongle Oral Liquid,using the montelukast sodium as the positive control.Results The immunoglobulin Ig E and interleukin( IL-4,IL-10) in asthmatic rats were significantly different between intragastric administration groups and the model group( P<0.05).Compare with the normal control group,the expression level of Ig E and interleukin( IL-4,IL-10) was not significantly different in intragastric administration groups( P>0.05). Conclusion Tongle Oral Liquid could significantly reduce the level of Ig E and IL-4 in asthmatic rats and increase the level of IL-10. The mechanism of inflammation may be related to inhibiting the activity of Th2 cytokines.
Objective To investigate the intervention effect and mechanism of Tongle Oral Liquid on asthmatic rats.Methods The rat model of asthma was induced by ovalbumin.The immunoglobulin Ig E and interleukin( IL-4,IL-10) in serum were detected by chemiluminescence methods. The asthmatic rats were treated with different doses of Tongle Oral Liquid,using the montelukast sodium as the positive control.Results The immunoglobulin Ig E and interleukin( IL-4,IL-10) in asthmatic rats were significantly different between intragastric administration groups and the model group( P<0.05).Compare with the normal control group,the expression level of Ig E and interleukin( IL-4,IL-10) was not significantly different in intragastric administration groups( P>0.05). Conclusion Tongle Oral Liquid could significantly reduce the level of Ig E and IL-4 in asthmatic rats and increase the level of IL-10. The mechanism of inflammation may be related to inhibiting the activity of Th2 cytokines.
引文
[1]BOULET L P,FITZGERALD J M,REDDEL H K.The revised 2014 GINA strategy report:opportunities for change[J].Curr Opin Pulm Med,2015,21(1):1-7.
[2]BUSSE W W,HOLGATE S,KERWIN E,et al.Randomized,double-blind,placebo-controlled study of brodalumab,a human anti-IL-17 receptor monoclonal antibody,in moderate to severe asthma[J].Am J Respir Crit Care Med,2013,188(11):1294-1302.
[3]姚丽敏,高丽.支气管哮喘发病机制研究进展[J].新疆中医药,2017,35(1):43-46.
[4]李明华,殷凯生,蔡映云.哮喘病学[M].北京:人民卫生出版社,2005:1.
[5]沈华浩.哮喘手册:第3版[M].北京:人民卫生出版社,2016:131,412.
[6]BARNES P J,PEDERSEN S,BUSSE W W.Efficacy and safety of inhaled corticosteroids.New development[J].Am J Respir Crit Care Med,1998,157(3 Pt 2):S1-S53.
[7]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案[J].中华结核和呼吸杂志,2003,26(3):132-138.
[8]康雅媛.冬病夏治中药穴位贴敷治疗儿童哮喘缓解期100例[J].江西中医药,2009,40(4):55.
[9]成华,徐明扬,葛振华,等.中药贴膏治疗儿童哮喘缓解期的临床观察[J].中医儿科杂志,2010,6(4):36-37.
[10]王瑛,温玉玲,杜萍,等.益气固本法治疗儿童哮喘缓解期疗效观察[J].中国中西医结合儿科学,2010,2(6):532-533.
[11]肖红,王响.中医治疗儿童咳嗽变异性哮喘概况[J].中医杂志,2013,54(2):167-169.
[12]王贵林,朱慧玲,张渊,等.童乐口服液的药效学研究[J].时珍国医国药,2006,17(2):211-212.
[13]李克彬,唐寅,杨佳奇,等.慢性气道炎症性疾病中细胞因子作用研究进展[J].中国公共卫生,2016,32(4):415-419.
[14]史锁芳,杨兴嫕,李萍.平哮颗粒药效学及抗炎机理研[J].中国中医急症,2014,23(6):1056-1059.
[15]BASEHORE M J,HOWARD T D,LANGE L A,et al.A comprehensive evaluation of IL4 variants in ethnically diverse populations:association of total serum Ig E levels and asthma in white subjects[J].J Allery Clin Immunol,2004,114(1):80-87.
[16]许令春,张德平.IL-4在支气管哮喘中的作用及中医药对其影响[J].医学综述,2007,13(17):1332-1334.
[17]邓民斌,胡苏荣,韦国桢.支气管哮喘患者血清IL-10与Ig E水平变化的研究[J].标记免疫分析与临床,2002,9(4):196-198.
[18]RIVERA A,COLLINS N,STEPHAN M T,et al.Aberrant tissue localization of fungus-specific CD4+T cells in IL-10-deficient mice[J].J Immunol,2009,183(1):631-641.
[19]KOSAKA S,TAMAUCHI H,TERASHIMA M,et al.IL-10controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation[J].Immnobiology,2011,216(7):811-820.
[2]BUSSE W W,HOLGATE S,KERWIN E,et al.Randomized,double-blind,placebo-controlled study of brodalumab,a human anti-IL-17 receptor monoclonal antibody,in moderate to severe asthma[J].Am J Respir Crit Care Med,2013,188(11):1294-1302.
[3]姚丽敏,高丽.支气管哮喘发病机制研究进展[J].新疆中医药,2017,35(1):43-46.
[4]李明华,殷凯生,蔡映云.哮喘病学[M].北京:人民卫生出版社,2005:1.
[5]沈华浩.哮喘手册:第3版[M].北京:人民卫生出版社,2016:131,412.
[6]BARNES P J,PEDERSEN S,BUSSE W W.Efficacy and safety of inhaled corticosteroids.New development[J].Am J Respir Crit Care Med,1998,157(3 Pt 2):S1-S53.
[7]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案[J].中华结核和呼吸杂志,2003,26(3):132-138.
[8]康雅媛.冬病夏治中药穴位贴敷治疗儿童哮喘缓解期100例[J].江西中医药,2009,40(4):55.
[9]成华,徐明扬,葛振华,等.中药贴膏治疗儿童哮喘缓解期的临床观察[J].中医儿科杂志,2010,6(4):36-37.
[10]王瑛,温玉玲,杜萍,等.益气固本法治疗儿童哮喘缓解期疗效观察[J].中国中西医结合儿科学,2010,2(6):532-533.
[11]肖红,王响.中医治疗儿童咳嗽变异性哮喘概况[J].中医杂志,2013,54(2):167-169.
[12]王贵林,朱慧玲,张渊,等.童乐口服液的药效学研究[J].时珍国医国药,2006,17(2):211-212.
[13]李克彬,唐寅,杨佳奇,等.慢性气道炎症性疾病中细胞因子作用研究进展[J].中国公共卫生,2016,32(4):415-419.
[14]史锁芳,杨兴嫕,李萍.平哮颗粒药效学及抗炎机理研[J].中国中医急症,2014,23(6):1056-1059.
[15]BASEHORE M J,HOWARD T D,LANGE L A,et al.A comprehensive evaluation of IL4 variants in ethnically diverse populations:association of total serum Ig E levels and asthma in white subjects[J].J Allery Clin Immunol,2004,114(1):80-87.
[16]许令春,张德平.IL-4在支气管哮喘中的作用及中医药对其影响[J].医学综述,2007,13(17):1332-1334.
[17]邓民斌,胡苏荣,韦国桢.支气管哮喘患者血清IL-10与Ig E水平变化的研究[J].标记免疫分析与临床,2002,9(4):196-198.
[18]RIVERA A,COLLINS N,STEPHAN M T,et al.Aberrant tissue localization of fungus-specific CD4+T cells in IL-10-deficient mice[J].J Immunol,2009,183(1):631-641.
[19]KOSAKA S,TAMAUCHI H,TERASHIMA M,et al.IL-10controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation[J].Immnobiology,2011,216(7):811-820.